Literature DB >> 25559408

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

Karen A Autio1, Azeez Farooki2, Ilya G Glezerman3, Amelia Chan4, Coursen W Schneider5, Hallie C Barr4, Brian M Seyboth4, Lewis J Kampel5, Daniel C Danila5, Dana E Rathkopf5, Susan F Slovin5, Howard I Scher5, Michael J Morris5.   

Abstract

Entities:  

Keywords:  Denosumab; Hypocalcemia; Metastatic prostate cancer; Osteoclast; RANKL; Skeletal-related event

Mesh：

Substances：

Year:  2014        PMID： 25559408      PMCID： PMC4985717          DOI： 10.1016/j.clgc.2014.11.008

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  17 in total

1.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

2.  Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer.

Authors:  M I Fokkema; L J M de Heide; W D van Schelven; N A T Hamdy
Journal:  Neth J Med       Date:  2005-01       Impact factor: 1.422

3.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Authors:  P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Richard J Cook; Robert Coleman; Janet Brown; Allan Lipton; Pierre Major; Yong Jiang Hei; Fred Saad; Matthew R Smith
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

8.  Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.

Authors:  Michael Lein; Kurt Miller; Manfred Wirth; Lothar Weissbach; Christoph May; Katja Schmidt; Ulrike Haus; Mark Schrader; Klaus Jung
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

9.  Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.

Authors:  James L Gulley; Shenhong Wu; Philip M Arlen; William L Dahut
Journal:  Clin Genitourin Cancer       Date:  2007-09       Impact factor: 2.872

10.  A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

Authors:  Andrew J Armstrong; Elizabeth S Garrett-Mayer; Yi-Chun Ou Yang; Ronald de Wit; Ian F Tannock; Mario Eisenberger
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531
View more
  12 in total

1.  Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.

Authors:  Kanramon Watthanasuntorn; Haisam Abid; Rosana Gnanajothy
Journal:  BMJ Case Rep       Date:  2018-12-13

2.  Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.

Authors:  Sameer Saleem; Sabah Patel; Adnan Ahmed; Nasir Saleem
Journal:  BMJ Case Rep       Date:  2018-05-30

3.  A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.

Authors:  Larissa K Laskowski; David S Goldfarb; Mary Ann Howland; Kelly Kavcsak; Danny M Lugassy; Silas W Smith
Journal:  J Med Toxicol       Date:  2016-03-17

4.  Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Azeez Farooki; Michael J Morris
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-07       Impact factor: 5.455

5.  Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

Review 6.  Hypercalcemia of malignancy and new treatment options.

Authors:  Hillel Sternlicht; Ilya G Glezerman
Journal:  Ther Clin Risk Manag       Date:  2015-12-04       Impact factor: 2.423

7.  High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.

Authors:  Koji Ishikawa; Takashi Nagai; Keizo Sakamoto; Kenji Ohara; Takeshi Eguro; Hiroshi Ito; Yoichi Toyoshima; Akatsuki Kokaze; Tomoaki Toyone; Katsunori Inagaki
Journal:  Ther Clin Risk Manag       Date:  2016-12-05       Impact factor: 2.423

8.  Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review.

Authors:  Christina F Marlow; Shailendra Sharma; Faizan Babar; Jianqing Lin
Journal:  Case Rep Oncol Med       Date:  2018-10-14

9.  Hypocalcemia Revealing an Enteropathy-Associated T-cell Lymphoma.

Authors:  Maria Belen Alonso Ortiz; Noel Lorenzo Villalba; Emilio Almaraz Marroquin; Melek Kechida; Manuel Mendez-Bailon; Imanol Pulido Gonzalez
Journal:  Caspian J Intern Med       Date:  2019

10.  SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.

Authors:  Rachael V McCaleb; Jill T Johnson
Journal:  AACE Clin Case Rep       Date:  2019-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.